FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097594301> ?p ?o ?g. }

• W3097594301 endingPage "100273" @default.
• W3097594301 startingPage "100273" @default.
• W3097594301 abstract "Background Hyperemesis gravidarum is a disabling disease of nausea, vomiting, and undernutrition in early pregnancy for which there are no effective outpatient therapies. Poor weight gain in hyperemesis gravidarum is associated with several adverse fetal outcomes including preterm delivery, low birthweight, small for gestational age, low 5-minute Apgar scores, and neurodevelopmental delay. Gabapentin is most commonly used clinically for treating neuropathic pain but also substantially reduces chemotherapy-induced and postoperative nausea and vomiting. Pregnancy registry data have shown maternal first-trimester gabapentin monotherapy to be associated with a 1.2% rate of major congenital malformations among 659 infants, which compares favorably with the 1.6% to 2.2% major congenital malformation rate in the general population. Open-label gabapentin treatment in hyperemesis gravidarum was associated with reduced nausea and vomiting and improved oral nutrition. Objective This study aimed to determine whether gabapentin is more effective than standard-of-care therapy for treating hyperemesis gravidarum. Study Design A double-blind, randomized, multicenter trial was conducted among patients with medically refractory hyperemesis gravidarum requiring intravenous hydration. Patients were randomized (1:1) to either oral gabapentin (1800–2400 mg/d) or an active comparator of either oral ondansetron (24–32 mg/d) or oral metoclopramide (45–60 mg/d) for 7 days. Differences in Motherisk–pregnancy-unique quantification of nausea and emesis total scores between treatment groups averaged over days 5 to 7, using intention-to-treat principle employing a linear mixed-effects model adjusted for baseline Motherisk–pregnancy-unique quantification of nausea and emesis scores, which served as the primary endpoint. Secondary outcomes included Motherisk–pregnancy-unique quantification of nausea and emesis nausea and vomit and retch subscores, oral nutrition, global satisfaction of treatment, relief, desire to continue therapy, Nausea and Vomiting of Pregnancy Quality of Life, and Hyperemesis Gravidarum Pregnancy Termination Consideration. Adjustments for multiple comparisons were made employing the false discovery rate. Results A total of 31 patients with hyperemesis gravidarum were enrolled from October 2014 to May 2019. Among the 21 patients providing primary outcome data (12 assigned to gabapentin and 9 to the active comparator arm), 18 were enrolled as outpatients and all 21 were outpatients from days 5 to 7. The study groups’ baseline characteristics were well matched. Gabapentin treatment provided a 52% greater reduction in days 5 to 7 baseline adjusted Motherisk–pregnancy-unique quantification of nausea and emesis total scores than treatment with active comparator (95% confidence interval, 16–88; P=.01). Most secondary outcomes also favored gabapentin over active comparator treatment including 46% and 49% decreases in baseline adjusted Motherisk–pregnancy-unique quantification of nausea and emesis nausea (95% confidence interval, 19–72; P=.005) and vomit and retch subscores (95% confidence interval, 21–77; P=.005), respectively; a 96% increase in baseline adjusted oral nutrition scores (95% confidence interval, 27–165; P=.01); and a 254% difference in global satisfaction of treatment (95% confidence interval, 48–459; P=.03). Relief (P=.06) and desire to continue therapy (P=.06) both showed trends favoring gabapentin treatment but Nausea and Vomiting of Pregnancy Quality of Life (P=.68) and Hyperemesis Gravidarum Pregnancy Termination Consideration (P=.58) did not. Adverse events were roughly equivalent between the groups. There were no serious adverse events. Conclusion In this small trial, gabapentin was more effective than standard-of-care therapy for reducing nausea and vomiting and increasing oral nutrition and global satisfaction in outpatients with hyperemesis gravidarum. These data build on previous findings in other patient populations supporting gabapentin as a novel antinausea and antiemetic therapy and support further research on gabapentin for this challenging complication of pregnancy. Hyperemesis gravidarum is a disabling disease of nausea, vomiting, and undernutrition in early pregnancy for which there are no effective outpatient therapies. Poor weight gain in hyperemesis gravidarum is associated with several adverse fetal outcomes including preterm delivery, low birthweight, small for gestational age, low 5-minute Apgar scores, and neurodevelopmental delay. Gabapentin is most commonly used clinically for treating neuropathic pain but also substantially reduces chemotherapy-induced and postoperative nausea and vomiting. Pregnancy registry data have shown maternal first-trimester gabapentin monotherapy to be associated with a 1.2% rate of major congenital malformations among 659 infants, which compares favorably with the 1.6% to 2.2% major congenital malformation rate in the general population. Open-label gabapentin treatment in hyperemesis gravidarum was associated with reduced nausea and vomiting and improved oral nutrition. This study aimed to determine whether gabapentin is more effective than standard-of-care therapy for treating hyperemesis gravidarum. A double-blind, randomized, multicenter trial was conducted among patients with medically refractory hyperemesis gravidarum requiring intravenous hydration. Patients were randomized (1:1) to either oral gabapentin (1800–2400 mg/d) or an active comparator of either oral ondansetron (24–32 mg/d) or oral metoclopramide (45–60 mg/d) for 7 days. Differences in Motherisk–pregnancy-unique quantification of nausea and emesis total scores between treatment groups averaged over days 5 to 7, using intention-to-treat principle employing a linear mixed-effects model adjusted for baseline Motherisk–pregnancy-unique quantification of nausea and emesis scores, which served as the primary endpoint. Secondary outcomes included Motherisk–pregnancy-unique quantification of nausea and emesis nausea and vomit and retch subscores, oral nutrition, global satisfaction of treatment, relief, desire to continue therapy, Nausea and Vomiting of Pregnancy Quality of Life, and Hyperemesis Gravidarum Pregnancy Termination Consideration. Adjustments for multiple comparisons were made employing the false discovery rate. A total of 31 patients with hyperemesis gravidarum were enrolled from October 2014 to May 2019. Among the 21 patients providing primary outcome data (12 assigned to gabapentin and 9 to the active comparator arm), 18 were enrolled as outpatients and all 21 were outpatients from days 5 to 7. The study groups’ baseline characteristics were well matched. Gabapentin treatment provided a 52% greater reduction in days 5 to 7 baseline adjusted Motherisk–pregnancy-unique quantification of nausea and emesis total scores than treatment with active comparator (95% confidence interval, 16–88; P=.01). Most secondary outcomes also favored gabapentin over active comparator treatment including 46% and 49% decreases in baseline adjusted Motherisk–pregnancy-unique quantification of nausea and emesis nausea (95% confidence interval, 19–72; P=.005) and vomit and retch subscores (95% confidence interval, 21–77; P=.005), respectively; a 96% increase in baseline adjusted oral nutrition scores (95% confidence interval, 27–165; P=.01); and a 254% difference in global satisfaction of treatment (95% confidence interval, 48–459; P=.03). Relief (P=.06) and desire to continue therapy (P=.06) both showed trends favoring gabapentin treatment but Nausea and Vomiting of Pregnancy Quality of Life (P=.68) and Hyperemesis Gravidarum Pregnancy Termination Consideration (P=.58) did not. Adverse events were roughly equivalent between the groups. There were no serious adverse events. In this small trial, gabapentin was more effective than standard-of-care therapy for reducing nausea and vomiting and increasing oral nutrition and global satisfaction in outpatients with hyperemesis gravidarum. These data build on previous findings in other patient populations supporting gabapentin as a novel antinausea and antiemetic therapy and support further research on gabapentin for this challenging complication of pregnancy." @default.
• W3097594301 created "2020-11-09" @default.
• W3097594301 creator A5016635612 @default.
• W3097594301 creator A5023051545 @default.
• W3097594301 creator A5036969102 @default.
• W3097594301 creator A5038069496 @default.
• W3097594301 creator A5049802075 @default.
• W3097594301 creator A5067026312 @default.
• W3097594301 creator A5067065808 @default.
• W3097594301 creator A5084228567 @default.
• W3097594301 date "2021-01-01" @default.
• W3097594301 modified "2023-10-16" @default.
• W3097594301 title "Effect of gabapentin on hyperemesis gravidarum: a double-blind, randomized controlled trial" @default.
• W3097594301 cites W1963586502 @default.
• W3097594301 cites W1976503675 @default.
• W3097594301 cites W1981708539 @default.
• W3097594301 cites W1983648652 @default.
• W3097594301 cites W1987154880 @default.
• W3097594301 cites W2016309025 @default.
• W3097594301 cites W2020399699 @default.
• W3097594301 cites W2021930066 @default.
• W3097594301 cites W2031855772 @default.
• W3097594301 cites W2035285899 @default.
• W3097594301 cites W2038401300 @default.
• W3097594301 cites W2040760227 @default.
• W3097594301 cites W2048738964 @default.
• W3097594301 cites W2053221247 @default.
• W3097594301 cites W2059060356 @default.
• W3097594301 cites W2073927539 @default.
• W3097594301 cites W2074091201 @default.
• W3097594301 cites W2078459760 @default.
• W3097594301 cites W2084459498 @default.
• W3097594301 cites W2085662780 @default.
• W3097594301 cites W2090593991 @default.
• W3097594301 cites W2101372308 @default.
• W3097594301 cites W2121224427 @default.
• W3097594301 cites W2122443254 @default.
• W3097594301 cites W2123969889 @default.
• W3097594301 cites W2128889152 @default.
• W3097594301 cites W2140030441 @default.
• W3097594301 cites W2145493866 @default.
• W3097594301 cites W2150019692 @default.
• W3097594301 cites W2159342662 @default.
• W3097594301 cites W2167513687 @default.
• W3097594301 cites W2168795110 @default.
• W3097594301 cites W2289073892 @default.
• W3097594301 cites W2325266334 @default.
• W3097594301 cites W2522438015 @default.
• W3097594301 cites W2529757628 @default.
• W3097594301 cites W2625462649 @default.
• W3097594301 cites W2762367953 @default.
• W3097594301 cites W2917530221 @default.
• W3097594301 cites W2950698933 @default.
• W3097594301 cites W4239507701 @default.
• W3097594301 doi "https://doi.org/10.1016/j.ajogmf.2020.100273" @default.
• W3097594301 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33451591" @default.
• W3097594301 hasPublicationYear "2021" @default.
• W3097594301 type Work @default.
• W3097594301 sameAs 3097594301 @default.
• W3097594301 citedByCount "3" @default.
• W3097594301 countsByYear W30975943012022 @default.
• W3097594301 crossrefType "journal-article" @default.
• W3097594301 hasAuthorship W3097594301A5016635612 @default.
• W3097594301 hasAuthorship W3097594301A5023051545 @default.
• W3097594301 hasAuthorship W3097594301A5036969102 @default.
• W3097594301 hasAuthorship W3097594301A5038069496 @default.
• W3097594301 hasAuthorship W3097594301A5049802075 @default.
• W3097594301 hasAuthorship W3097594301A5067026312 @default.
• W3097594301 hasAuthorship W3097594301A5067065808 @default.
• W3097594301 hasAuthorship W3097594301A5084228567 @default.
• W3097594301 hasBestOaLocation W30975943011 @default.
• W3097594301 hasConcept C126322002 @default.
• W3097594301 hasConcept C131872663 @default.
• W3097594301 hasConcept C142724271 @default.
• W3097594301 hasConcept C168563851 @default.
• W3097594301 hasConcept C204787440 @default.
• W3097594301 hasConcept C27081682 @default.
• W3097594301 hasConcept C2776608144 @default.
• W3097594301 hasConcept C2778409550 @default.
• W3097594301 hasConcept C2780580376 @default.
• W3097594301 hasConcept C2991744798 @default.
• W3097594301 hasConcept C42219234 @default.
• W3097594301 hasConcept C71924100 @default.
• W3097594301 hasConceptScore W3097594301C126322002 @default.
• W3097594301 hasConceptScore W3097594301C131872663 @default.
• W3097594301 hasConceptScore W3097594301C142724271 @default.
• W3097594301 hasConceptScore W3097594301C168563851 @default.
• W3097594301 hasConceptScore W3097594301C204787440 @default.
• W3097594301 hasConceptScore W3097594301C27081682 @default.
• W3097594301 hasConceptScore W3097594301C2776608144 @default.
• W3097594301 hasConceptScore W3097594301C2778409550 @default.
• W3097594301 hasConceptScore W3097594301C2780580376 @default.
• W3097594301 hasConceptScore W3097594301C2991744798 @default.
• W3097594301 hasConceptScore W3097594301C42219234 @default.
• W3097594301 hasConceptScore W3097594301C71924100 @default.
• W3097594301 hasFunder F4320337611 @default.
• W3097594301 hasIssue "1" @default.
• W3097594301 hasLocation W30975943011 @default.

• next